Current Diabetes Reports

, Volume 12, Issue 5, pp 604–611

Risks, Benefits, and Therapeutic Potential of Hematopoietic Stem Cell Transplantation for Autoimmune Diabetes

  • Carlos Eduardo Barra Couri
  • Maria Carolina de Oliveira
  • Belinda Pinto Simões
Transplantation (A Pileggi, Section Editor)

DOI: 10.1007/s11892-012-0309-0

Cite this article as:
Couri, C.E.B., de Oliveira, M.C. & Simões, B.P. Curr Diab Rep (2012) 12: 604. doi:10.1007/s11892-012-0309-0

Abstract

Type 1 diabetes mellitus is a chronic disease that results from the autoimmune response against pancreatic insulin producing β cells. Apart of several insulin regimens, since the decade of 80s various immunomodulatory regimens were tested aiming at blocking some steps of the autoimmune process against β cell mass and at promoting β cell preservation. In the last years, some independent research groups tried to cure type 1 diabetes with an “immunologic reset” provided by autologous hematopoietic stem cell transplantation in newly diagnosed patients, and the majority of patients became free form insulin with increasing levels of C-peptide along the time. In this review, we discuss the biology of hematopoietic stem cells and the possible advantages and disadvantages related to the high dose immunosuppression followed by autologous hematopoietic stem cell transplantation.

Keywords

Type 1 diabetesStem cellHematopoieticCureDiabetesImmunosuppressionAutologous transplantationAutoimmune diabetes

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Carlos Eduardo Barra Couri
    • 1
  • Maria Carolina de Oliveira
    • 1
  • Belinda Pinto Simões
    • 1
  1. 1.Bone Marrow Transplantation Unit of the School of Medicine of Ribeirão PretoRibeirão PretoBrazil